Comparison of dimethyl fumarate and interferon outcomes in an MS cohort
Background To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing–remitting Multiple Sclerosis (MS). Methods Clinical and imaging data from patients treated with either IFNβ-1a or DMF for at le...
Gespeichert in:
| Veröffentlicht in: | BMC neurology Jg. 22; H. 1; S. 1 - 8 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
11.07.2022
BioMed Central Ltd Springer Nature B.V BMC |
| Schlagworte: | |
| ISSN: | 1471-2377, 1471-2377 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing–remitting Multiple Sclerosis (MS).
Methods
Clinical and imaging data from patients treated with either IFNβ-1a or DMF for at least one year were reviewed. The proportion of patients with at least one clinical relapse within 3–15 months after treatment onset, the proportion of patients with new T2 or gadolinium-enhancing lesions, and the proportion of subjects who achieved no evidence of disease activity (NEDA) status were assessed.
Results
Three hundred sixteen (98 on IFNβ-1a, 218 on DMF) subjects were included. Baseline demographics were comparable between groups except for age, disease duration, and the number of previous treatments being higher and relapse rate in the prior year being lower in the DMF-treated group. The proportion of patients having a clinical relapse (24.5% vs. 9.6%; OR = 3.04;
P
< 0.001) or a new MRI lesion (28.6% vs. 8.7%; OR = 4.19,
P
< 0.001) at 15 months were higher on IFNβ-1a. 79.9% of the patients achieved NEDA status at 15 months on DMF (vs. 51.1% for IFNβ-1a; OR = 0.26,
P
< 0.001). Further adjustment for demographics, disease characteristics, treatment and relapse history, and subgroup analyses confirmed these findings.
Conclusion
DMF was associated with less clinical and radiological disease activity compared to IFNβ-1a. |
|---|---|
| AbstractList | Abstract Background To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing–remitting Multiple Sclerosis (MS). Methods Clinical and imaging data from patients treated with either IFNβ-1a or DMF for at least one year were reviewed. The proportion of patients with at least one clinical relapse within 3–15 months after treatment onset, the proportion of patients with new T2 or gadolinium-enhancing lesions, and the proportion of subjects who achieved no evidence of disease activity (NEDA) status were assessed. Results Three hundred sixteen (98 on IFNβ-1a, 218 on DMF) subjects were included. Baseline demographics were comparable between groups except for age, disease duration, and the number of previous treatments being higher and relapse rate in the prior year being lower in the DMF-treated group. The proportion of patients having a clinical relapse (24.5% vs. 9.6%; OR = 3.04; P < 0.001) or a new MRI lesion (28.6% vs. 8.7%; OR = 4.19, P < 0.001) at 15 months were higher on IFNβ-1a. 79.9% of the patients achieved NEDA status at 15 months on DMF (vs. 51.1% for IFNβ-1a; OR = 0.26, P < 0.001). Further adjustment for demographics, disease characteristics, treatment and relapse history, and subgroup analyses confirmed these findings. Conclusion DMF was associated with less clinical and radiological disease activity compared to IFNβ-1a. To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFN[beta]-1a) in controlling disease activity in patients with relapsing-remitting Multiple Sclerosis (MS). Clinical and imaging data from patients treated with either IFN[beta]-1a or DMF for at least one year were reviewed. The proportion of patients with at least one clinical relapse within 3-15 months after treatment onset, the proportion of patients with new T2 or gadolinium-enhancing lesions, and the proportion of subjects who achieved no evidence of disease activity (NEDA) status were assessed. Three hundred sixteen (98 on IFN[beta]-1a, 218 on DMF) subjects were included. Baseline demographics were comparable between groups except for age, disease duration, and the number of previous treatments being higher and relapse rate in the prior year being lower in the DMF-treated group. The proportion of patients having a clinical relapse (24.5% vs. 9.6%; OR = 3.04; P < 0.001) or a new MRI lesion (28.6% vs. 8.7%; OR = 4.19, P < 0.001) at 15 months were higher on IFN[beta]-1a. 79.9% of the patients achieved NEDA status at 15 months on DMF (vs. 51.1% for IFN[beta]-1a; OR = 0.26, P < 0.001). Further adjustment for demographics, disease characteristics, treatment and relapse history, and subgroup analyses confirmed these findings. DMF was associated with less clinical and radiological disease activity compared to IFN[beta]-1a. To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing-remitting Multiple Sclerosis (MS).BACKGROUNDTo compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing-remitting Multiple Sclerosis (MS).Clinical and imaging data from patients treated with either IFNβ-1a or DMF for at least one year were reviewed. The proportion of patients with at least one clinical relapse within 3-15 months after treatment onset, the proportion of patients with new T2 or gadolinium-enhancing lesions, and the proportion of subjects who achieved no evidence of disease activity (NEDA) status were assessed.METHODSClinical and imaging data from patients treated with either IFNβ-1a or DMF for at least one year were reviewed. The proportion of patients with at least one clinical relapse within 3-15 months after treatment onset, the proportion of patients with new T2 or gadolinium-enhancing lesions, and the proportion of subjects who achieved no evidence of disease activity (NEDA) status were assessed.Three hundred sixteen (98 on IFNβ-1a, 218 on DMF) subjects were included. Baseline demographics were comparable between groups except for age, disease duration, and the number of previous treatments being higher and relapse rate in the prior year being lower in the DMF-treated group. The proportion of patients having a clinical relapse (24.5% vs. 9.6%; OR = 3.04; P < 0.001) or a new MRI lesion (28.6% vs. 8.7%; OR = 4.19, P < 0.001) at 15 months were higher on IFNβ-1a. 79.9% of the patients achieved NEDA status at 15 months on DMF (vs. 51.1% for IFNβ-1a; OR = 0.26, P < 0.001). Further adjustment for demographics, disease characteristics, treatment and relapse history, and subgroup analyses confirmed these findings.RESULTSThree hundred sixteen (98 on IFNβ-1a, 218 on DMF) subjects were included. Baseline demographics were comparable between groups except for age, disease duration, and the number of previous treatments being higher and relapse rate in the prior year being lower in the DMF-treated group. The proportion of patients having a clinical relapse (24.5% vs. 9.6%; OR = 3.04; P < 0.001) or a new MRI lesion (28.6% vs. 8.7%; OR = 4.19, P < 0.001) at 15 months were higher on IFNβ-1a. 79.9% of the patients achieved NEDA status at 15 months on DMF (vs. 51.1% for IFNβ-1a; OR = 0.26, P < 0.001). Further adjustment for demographics, disease characteristics, treatment and relapse history, and subgroup analyses confirmed these findings.DMF was associated with less clinical and radiological disease activity compared to IFNβ-1a.CONCLUSIONDMF was associated with less clinical and radiological disease activity compared to IFNβ-1a. Background To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFN[beta]-1a) in controlling disease activity in patients with relapsing-remitting Multiple Sclerosis (MS). Methods Clinical and imaging data from patients treated with either IFN[beta]-1a or DMF for at least one year were reviewed. The proportion of patients with at least one clinical relapse within 3-15 months after treatment onset, the proportion of patients with new T2 or gadolinium-enhancing lesions, and the proportion of subjects who achieved no evidence of disease activity (NEDA) status were assessed. Results Three hundred sixteen (98 on IFN[beta]-1a, 218 on DMF) subjects were included. Baseline demographics were comparable between groups except for age, disease duration, and the number of previous treatments being higher and relapse rate in the prior year being lower in the DMF-treated group. The proportion of patients having a clinical relapse (24.5% vs. 9.6%; OR = 3.04; P < 0.001) or a new MRI lesion (28.6% vs. 8.7%; OR = 4.19, P < 0.001) at 15 months were higher on IFN[beta]-1a. 79.9% of the patients achieved NEDA status at 15 months on DMF (vs. 51.1% for IFN[beta]-1a; OR = 0.26, P < 0.001). Further adjustment for demographics, disease characteristics, treatment and relapse history, and subgroup analyses confirmed these findings. Conclusion DMF was associated with less clinical and radiological disease activity compared to IFN[beta]-1a. Keywords: Multiple sclerosis, Dimethyl fumarate, Interferon, Disease activity, Effectiveness, Cohort Background To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing–remitting Multiple Sclerosis (MS). Methods Clinical and imaging data from patients treated with either IFNβ-1a or DMF for at least one year were reviewed. The proportion of patients with at least one clinical relapse within 3–15 months after treatment onset, the proportion of patients with new T2 or gadolinium-enhancing lesions, and the proportion of subjects who achieved no evidence of disease activity (NEDA) status were assessed. Results Three hundred sixteen (98 on IFNβ-1a, 218 on DMF) subjects were included. Baseline demographics were comparable between groups except for age, disease duration, and the number of previous treatments being higher and relapse rate in the prior year being lower in the DMF-treated group. The proportion of patients having a clinical relapse (24.5% vs. 9.6%; OR = 3.04; P < 0.001) or a new MRI lesion (28.6% vs. 8.7%; OR = 4.19, P < 0.001) at 15 months were higher on IFNβ-1a. 79.9% of the patients achieved NEDA status at 15 months on DMF (vs. 51.1% for IFNβ-1a; OR = 0.26, P < 0.001). Further adjustment for demographics, disease characteristics, treatment and relapse history, and subgroup analyses confirmed these findings. Conclusion DMF was associated with less clinical and radiological disease activity compared to IFNβ-1a. Background To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing–remitting Multiple Sclerosis (MS). Methods Clinical and imaging data from patients treated with either IFNβ-1a or DMF for at least one year were reviewed. The proportion of patients with at least one clinical relapse within 3–15 months after treatment onset, the proportion of patients with new T2 or gadolinium-enhancing lesions, and the proportion of subjects who achieved no evidence of disease activity (NEDA) status were assessed. Results Three hundred sixteen (98 on IFNβ-1a, 218 on DMF) subjects were included. Baseline demographics were comparable between groups except for age, disease duration, and the number of previous treatments being higher and relapse rate in the prior year being lower in the DMF-treated group. The proportion of patients having a clinical relapse (24.5% vs. 9.6%; OR = 3.04; P < 0.001) or a new MRI lesion (28.6% vs. 8.7%; OR = 4.19, P < 0.001) at 15 months were higher on IFNβ-1a. 79.9% of the patients achieved NEDA status at 15 months on DMF (vs. 51.1% for IFNβ-1a; OR = 0.26, P < 0.001). Further adjustment for demographics, disease characteristics, treatment and relapse history, and subgroup analyses confirmed these findings. Conclusion DMF was associated with less clinical and radiological disease activity compared to IFNβ-1a. |
| ArticleNumber | 252 |
| Audience | Academic |
| Author | Sattarnezhad, Neda Stankiewicz, James Chitnis, Tanuja Weiner, Howard L. Healy, Brian C. Baharnoori, Moogeh Diaz-Cruz, Camilo |
| Author_xml | – sequence: 1 givenname: Neda surname: Sattarnezhad fullname: Sattarnezhad, Neda organization: Harvard Medical School, Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital – sequence: 2 givenname: Brian C. surname: Healy fullname: Healy, Brian C. organization: Harvard Medical School, Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital, Biostatistics Center, Massachusetts General Hospital – sequence: 3 givenname: Moogeh surname: Baharnoori fullname: Baharnoori, Moogeh organization: Harvard Medical School, Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital – sequence: 4 givenname: Camilo surname: Diaz-Cruz fullname: Diaz-Cruz, Camilo organization: Harvard Medical School, Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital – sequence: 5 givenname: James surname: Stankiewicz fullname: Stankiewicz, James organization: Harvard Medical School, Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital – sequence: 6 givenname: Howard L. surname: Weiner fullname: Weiner, Howard L. organization: Harvard Medical School, Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital – sequence: 7 givenname: Tanuja surname: Chitnis fullname: Chitnis, Tanuja email: tchitnis@rics.bwh.harvard.edu organization: Harvard Medical School, Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital |
| BookMark | eNp9kk1rFTEUhgep2A_9A64G3LiZms9JZiOUi9ZCxYW6DpnMyb25zCTXJCP035vpVOotUkJIOHneNznhPa9OfPBQVW8xusRYth8SJlLSBhFSpmhxI19UZ5gJ3BAqxMk_-9PqPKU9QlhIhl9Vp5RLgiQhZ9X1JkwHHV0Kvg62HtwEeXc31naedNQZau2H2vkM0UJcmDmbMEEqtXJUf_1em7ALMb-uXlo9JnjzsF5UPz9_-rH50tx-u77ZXN02hkuWG0nLO4FTwfrODqLlPQPaSs0p7bnGklvZ0l5zQXDPqRRMM2I6STEzEgxoelHdrL5D0Ht1iK48804F7dR9IcSt0jE7M4IahKUAuJW8t6wzphdItKxDmAOhtO2K18fV6zD3EwwGfI56PDI9PvFup7bht-qIEBKjYvD-wSCGXzOkrCaXDIyj9hDmpEgrO9QiTBb03RN0H-boy1cVqsOctYzwR2qrSwPO21DuNYupuhIYIYqkkIW6_A9VxgCTMyUj1pX6kUCuAhNDShGsMi7r7MLSlhsVRmoJlFoDpUqg1H2g1CIlT6R_v-dZEV1FqcB-C_Gx2WdUfwCCWtsM |
| CitedBy_id | crossref_primary_10_57264_cer_2023_0161 crossref_primary_10_3389_fninf_2025_1519391 crossref_primary_10_1007_s12325_024_02901_1 crossref_primary_10_1007_s00415_023_12113_2 crossref_primary_10_1016_j_jns_2024_122913 crossref_primary_10_57264_cer_2025_0061 |
| Cites_doi | 10.1002/ana.64 10.1212/WNL.43.4.662 10.1185/03007995.2013.849236 10.1001/jamaneurol.2014.3537 10.1177/1352458516649037 10.1016/j.autrev.2006.02.012 10.1002/ana.22366 10.1002/14651858.CD011381.pub2 10.1007/s00415-020-10226-6 10.1093/brain/awq118 10.1016/S0140-6736(08)61619-0 10.1016/S1474-4422(11)70043-6 10.1212/01.WNL.0000078885.05053.7D 10.1136/jnnp.2008.145805 10.1212/WNL.0b013e31823648b9 10.1177/1352458510394702 10.1016/j.molmed.2013.03.004 10.1212/WNL.0b013e31824e8ee7 10.1056/NEJMoa0907839 10.1056/NEJMoa0802670 10.1212/WNL.78.1_MeetingAbstracts.PD5.005 10.1016/j.ncl.2010.12.010 10.1212/WNL.33.11.1444 10.1016/S0140-6736(12)61769-3 10.1016/S1474-4422(11)70020-5 10.1016/S1474-4422(09)70226-1 10.1016/S0140-6736(98)03334-0 10.1038/s41582-021-00556-y 10.1016/S1474-4422(08)70200-X 10.1002/ana.410390304 10.1056/NEJMoa1206328 10.1111/j.1468-1331.2006.01292.x 10.1016/j.msard.2013.06.004 10.1177/1756285614564152 10.1056/NEJMoa1114287 10.1016/j.clinthera.2007.09.025 10.1007/s13311-020-01001-6 10.1212/01.WNL.0000034080.43681.DA |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). |
| Copyright_xml | – notice: The Author(s) 2022 – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). |
| DBID | C6C AAYXX CITATION 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12883-022-02761-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) Neurosciences Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2377 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_d7f3ee1685bf49ccb707649015e23369 PMC9277810 A710030878 10_1186_s12883_022_02761_8 |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: National Multiple Sclerosis Society grantid: RG- 4256A4/2 funderid: http://dx.doi.org/10.13039/100000890 – fundername: EMD Serono grantid: CLIMB A2 funderid: http://dx.doi.org/10.13039/100004755 – fundername: ; grantid: CLIMB A2 – fundername: ; grantid: RG- 4256A4/2 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IGS IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION 3V. 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c584t-83761e5374b9fd765b4e368a533b5a185f863ba5721b53874a42c98314c8ecea3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 6 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000824926600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2377 |
| IngestDate | Fri Oct 03 12:36:03 EDT 2025 Tue Nov 04 01:59:58 EST 2025 Sun Nov 09 13:35:18 EST 2025 Thu Oct 09 21:51:52 EDT 2025 Tue Nov 11 10:23:26 EST 2025 Tue Nov 04 17:55:18 EST 2025 Sat Nov 29 01:40:04 EST 2025 Tue Nov 18 21:47:01 EST 2025 Sat Sep 06 07:36:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Multiple sclerosis Interferon Disease activity Effectiveness Cohort Dimethyl fumarate |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c584t-83761e5374b9fd765b4e368a533b5a185f863ba5721b53874a42c98314c8ecea3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/d7f3ee1685bf49ccb707649015e23369 |
| PMID | 35820822 |
| PQID | 2691546425 |
| PQPubID | 44772 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d7f3ee1685bf49ccb707649015e23369 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9277810 proquest_miscellaneous_2689060120 proquest_journals_2691546425 gale_infotracmisc_A710030878 gale_infotracacademiconefile_A710030878 crossref_citationtrail_10_1186_s12883_022_02761_8 crossref_primary_10_1186_s12883_022_02761_8 springer_journals_10_1186_s12883_022_02761_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-07-11 |
| PublicationDateYYYYMMDD | 2022-07-11 |
| PublicationDate_xml | – month: 07 year: 2022 text: 2022-07-11 day: 11 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | BMC neurology |
| PublicationTitleAbbrev | BMC Neurol |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | DL Rotstein (2761_CR37) 2015; 72 CH Polman (2761_CR18) 2011; 69 E D’Amico (2761_CR25) 2021; 18 G Comi (2761_CR8) 2001; 49 SA Gauthier (2761_CR16) 2006; 5 L Kappos (2761_CR13) 2008; 372 JF Kurtzke (2761_CR17) 1983; 33 JA Cohen (2761_CR24) 2010; 362 DW Paty (2761_CR4) 1993; 43 DD Mikol (2761_CR7) 2008; 7 N Koch-Henriksen (2761_CR26) 2021; 17 J Lorscheider (2761_CR23) 2021; 268 LD Jacobs (2761_CR6) 1996; 39 R Gold (2761_CR14) 2012; 367 A Haghikia (2761_CR2) 2013; 19 P O'Connor (2761_CR5) 2009; 8 M Calabrese (2761_CR33) 2012; 18 R Bomprezzi (2761_CR12) 2015; 8 AJ Coles (2761_CR32) 2011; 10 SR Schwid (2761_CR27) 2007; 29 GC Ebers (2761_CR9) 1998; 352 H Panitch (2761_CR28) 2002; 59 HP Hartung (2761_CR34) 2011; 10 RJ Fox (2761_CR11) 2014; 30 S Schimrigk (2761_CR10) 2006; 13 SV Ramagopalan (2761_CR1) 2011; 29 R Gold (2761_CR20) 2017; 23 2761_CR31 MP Sormani (2761_CR35) 2011; 77 HL Tremlett (2761_CR3) 2003; 61 LA Benson (2761_CR22) 2014; 3 RJ Fox (2761_CR15) 2012; 367 2761_CR19 A Coles (2761_CR30) 2012; 78 2761_CR38 JA Cohen (2761_CR29) 2012; 380 A Scalfari (2761_CR36) 2010; 133 H Tremlett (2761_CR21) 2008; 79 |
| References_xml | – volume: 49 start-page: 290 issue: 3 year: 2001 ident: 2761_CR8 publication-title: Ann Neurol. doi: 10.1002/ana.64 – volume: 43 start-page: 662 issue: 4 year: 1993 ident: 2761_CR4 publication-title: Neurology. doi: 10.1212/WNL.43.4.662 – volume: 30 start-page: 251 issue: 2 year: 2014 ident: 2761_CR11 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2013.849236 – volume: 72 start-page: 152 issue: 2 year: 2015 ident: 2761_CR37 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2014.3537 – volume: 23 start-page: 253 issue: 2 year: 2017 ident: 2761_CR20 publication-title: Mult Scler J doi: 10.1177/1352458516649037 – volume: 5 start-page: 532 issue: 8 year: 2006 ident: 2761_CR16 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2006.02.012 – volume: 69 start-page: 292 issue: 2 year: 2011 ident: 2761_CR18 publication-title: Ann Neurol doi: 10.1002/ana.22366 – ident: 2761_CR19 doi: 10.1002/14651858.CD011381.pub2 – volume: 268 start-page: 941 issue: 3 year: 2021 ident: 2761_CR23 publication-title: J Neurol doi: 10.1007/s00415-020-10226-6 – volume: 133 start-page: 1914 issue: 7 year: 2010 ident: 2761_CR36 publication-title: Brain doi: 10.1093/brain/awq118 – volume: 372 start-page: 1463 issue: 9648 year: 2008 ident: 2761_CR13 publication-title: Lancet doi: 10.1016/S0140-6736(08)61619-0 – volume: 10 start-page: 293 issue: 4 year: 2011 ident: 2761_CR34 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(11)70043-6 – volume: 61 start-page: 551 issue: 4 year: 2003 ident: 2761_CR3 publication-title: Neurology doi: 10.1212/01.WNL.0000078885.05053.7D – volume: 79 start-page: 1368 issue: 12 year: 2008 ident: 2761_CR21 publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp.2008.145805 – volume: 77 start-page: 1684 issue: 18 year: 2011 ident: 2761_CR35 publication-title: Neurology doi: 10.1212/WNL.0b013e31823648b9 – volume: 18 start-page: 418 issue: 4 year: 2012 ident: 2761_CR33 publication-title: Mult Scler J doi: 10.1177/1352458510394702 – volume: 19 start-page: 309 issue: 5 year: 2013 ident: 2761_CR2 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2013.03.004 – volume: 78 start-page: 1069 issue: 14 year: 2012 ident: 2761_CR30 publication-title: Neurology doi: 10.1212/WNL.0b013e31824e8ee7 – volume: 362 start-page: 402 issue: 5 year: 2010 ident: 2761_CR24 publication-title: N Engl J Med doi: 10.1056/NEJMoa0907839 – ident: 2761_CR31 doi: 10.1056/NEJMoa0802670 – ident: 2761_CR38 doi: 10.1212/WNL.78.1_MeetingAbstracts.PD5.005 – volume: 29 start-page: 207 issue: 2 year: 2011 ident: 2761_CR1 publication-title: Neurol Clin doi: 10.1016/j.ncl.2010.12.010 – volume: 33 start-page: 1444 issue: 11 year: 1983 ident: 2761_CR17 publication-title: Neurology. doi: 10.1212/WNL.33.11.1444 – volume: 380 start-page: 1819 issue: 9856 year: 2012 ident: 2761_CR29 publication-title: Lancet doi: 10.1016/S0140-6736(12)61769-3 – volume: 10 start-page: 338 issue: 4 year: 2011 ident: 2761_CR32 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(11)70020-5 – volume: 8 start-page: 889 issue: 10 year: 2009 ident: 2761_CR5 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(09)70226-1 – volume: 352 start-page: 1498 issue: 9139 year: 1998 ident: 2761_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(98)03334-0 – volume: 17 start-page: 676 issue: 11 year: 2021 ident: 2761_CR26 publication-title: Nat Rev Neurol doi: 10.1038/s41582-021-00556-y – volume: 7 start-page: 903 issue: 10 year: 2008 ident: 2761_CR7 publication-title: The Lancet Neurology. doi: 10.1016/S1474-4422(08)70200-X – volume: 39 start-page: 285 issue: 3 year: 1996 ident: 2761_CR6 publication-title: Ann Neurol doi: 10.1002/ana.410390304 – volume: 367 start-page: 1087 issue: 12 year: 2012 ident: 2761_CR15 publication-title: N Engl J Med doi: 10.1056/NEJMoa1206328 – volume: 13 start-page: 604 issue: 6 year: 2006 ident: 2761_CR10 publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2006.01292.x – volume: 3 start-page: 186 issue: 2 year: 2014 ident: 2761_CR22 publication-title: Multiple Scleros Rel Disord doi: 10.1016/j.msard.2013.06.004 – volume: 8 start-page: 20 issue: 1 year: 2015 ident: 2761_CR12 publication-title: Ther Adv Neurol Disord doi: 10.1177/1756285614564152 – volume: 367 start-page: 1098 issue: 12 year: 2012 ident: 2761_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa1114287 – volume: 29 start-page: 2031 issue: 9 year: 2007 ident: 2761_CR27 publication-title: Clin Ther doi: 10.1016/j.clinthera.2007.09.025 – volume: 18 start-page: 905 issue: 2 year: 2021 ident: 2761_CR25 publication-title: Neurotherapeutics doi: 10.1007/s13311-020-01001-6 – volume: 59 start-page: 1496 issue: 10 year: 2002 ident: 2761_CR28 publication-title: Neurology doi: 10.1212/01.WNL.0000034080.43681.DA |
| SSID | ssj0017841 |
| Score | 2.3409615 |
| Snippet | Background
To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients... Background To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFN[beta]-1a) in controlling disease activity in... To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFN[beta]-1a) in controlling disease activity in patients with... Background To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients... To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with... Abstract Background To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous interferon beta-1a (IFNβ-1a) in controlling disease activity in... |
| SourceID | doaj pubmedcentral proquest gale crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1 |
| SubjectTerms | Clinical trials Cohort Comparative analysis Demographics Demography Dimethyl fumarate Disease activity Drug therapy Effectiveness Gadolinium Interferon Medicine Medicine & Public Health Multiple sclerosis Neurochemistry Neurology Neurosurgery Patient outcomes Patients β-Interferon |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgixAX3oilLQoSEgewuo4dP05VW7Vw6ariIfVmOY5TVqqSkmSR-PfMZJ1UoWovXGNbtjPvzOQbQt4r4SV25aYsdRCgiNJQDXaKLoTnSpRcmLLom02o5VKfn5uz-MGtjWWVg07sFXVRe_xGvpdKA9YevOVs_-oXxa5RmF2NLTTuky1EKhMzsnV4vDz7OuYRMKs2_Cqj5V7LsLkuxQp2CMcko3pijnrU_pu6-Wa95D9J094WnTz531s8JY-jF5ocbNjmGbkXqufk4WnMs78gn4_G9oRJXSbFChtN_7lMSizIBu80cVWRINJEU4YG56w72D-08AyGktNvCTbebbqX5MfJ8fejLzS2XKAePJGOQrgqWciATDkQScksF4FL7cApzDMHtr3Ukucug7gxB1WphBOpN5oz4XXwwfFXZFbVVXhNEh-yovAQAReGiywE7SDyXPg040XKeTBzwoY3b33EI8e2GJe2j0u0tBtqWaCW7all9Zx8HNdcbdA47px9iAQdZyKSdv-gbi5sFExbqJKHwKTO8lIY73O1UFKglxTgmBKO-QHZwaK8w_G8i78twCUROcseIDwSwirCdjuTmSCnfjo8sISNeqK11_wwJ-_GYVyJtW9VqNc4RxtEzUkXc6ImjDi52XSkWv3sscJNqpRmsPLTwLLXm9_-5t7cfdZt8ijtZUhRxnbIrGvWYZc88L-7Vdu8jTL4F5XqNlI priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9UwDI9gILQL34gHAwUJiQNUvDTfxzExuGxCDNBuUZom40lTH2r7JvHfY-e1RWWABNfGUVLHjm3Z-ZmQ51oEhV25C1Z6CFBEsoUBO1UsReBaJC5sqnOzCX18bE5P7YfhUVg3VruPKcl8U2e1Nup1x7AxboHV5xBKKVaYq-QamDuD6vjx5MuUO8BM2vg85rfzZiYoI_Vfvo8v10j-kijN9ufw1v_t_Da5OfibdH8rIHfIldjcJTeOhoz6PfLuYGpESNeJ1itsKf39nCYsvQY_lPqmpogp0abYIs2mh0VjB99giB6dUGyx2_b3yefDt58O3hdDc4UigM_RFxCYKhYlHEgFx6GVrETkynhw_yrpwYono3jlJUSIFVyKWnhRBms4E8HEED1_QHaadRMfEhqirOsAsW5tuZAxGg8x5jKUktcl59EuCBv57cKAPI4NMM5djkCMclsOOeCQyxxyZkFeTnO-bXE3_kr9Bo9xokTM7Pxh3Z65QQVdrROPkSkjqyRsCJVeaiXQH4qwTQXbfIFC4FCzYXvBDw8U4CcRI8vtIxASAijCcnszStDIMB8excgNN0LnSmXBW4VoTy7Is2kYZ2KVWxPXG6QxFvFxyuWC6Jn4zf5sPtKsvmZUcFtqbRjMfDUK4c_F_8y5R_9G_pjsllmOdcHYHtnp2018Qq6Hi37VtU-zHv4AQ24rIg priority: 102 providerName: Springer Nature |
| Title | Comparison of dimethyl fumarate and interferon outcomes in an MS cohort |
| URI | https://link.springer.com/article/10.1186/s12883-022-02761-8 https://www.proquest.com/docview/2691546425 https://www.proquest.com/docview/2689060120 https://pubmed.ncbi.nlm.nih.gov/PMC9277810 https://doaj.org/article/d7f3ee1685bf49ccb707649015e23369 |
| Volume | 22 |
| WOSCitedRecordID | wos000824926600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink Contemporary customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEB-0ivgifmK0HhEEHzT0NrvZj8e2tOrDHUercj4tyWZDD0pOcrlC_3tnNslpLOqLL4FkZ0kymcnMj539DcAbJZykrtwJS3MEKKIyicY4lUyF40pUXJiqDM0m1Hyul0uz-KXVF9WEdfTAneIOSlVx75nUWVEJ41yhEHkLimI-5VyGrXuY9Qxgql8_oNW0YYuMlgcbRk11E6pcRxgmWaJHYSiw9d_8J9-sk_xtsTTEoNOH8KBPHuPD7qEfwS1fP4Z7s355_Al8ON51FYzXVVyuqD_09WVcUR01JpVxXpcxEUQ0lW9IZtuiwfkNXsOheHYeU7_cpn0KX05PPh9_TPpOCYnDBKJNEGVK5jPUboG6VTIrhOdS55jLFVmOIbnSkhd5hnCvwD-cErlIndGcCae98zl_Bnv1uvbPIXY-K0uHwLU0XGTe6xwB49SlGS9R395EwAbFWdfTiFM3i0sb4ISWtlO2RWXboGyrI3i3m_O9I9H4q_QRfY-dJBFghwtoFrY3C_svs4jgLX1NS26Kj-fyfrcBviQRXtlDYjUiNkS83f5IEt3LjYcHe7C9e29sKg2mngjdsghe74ZpJpWs1X69JRltiOwmnUagRnY0erPxSL26CBTfJlVKM5z5frC4nzf_s-Ze_A_NvYT7aXAUlTC2D3tts_Wv4K67alebZgK31VKFo57AnaOT-eJsElwPzxafZotveHZ2_vUHepgskw |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCFN2KhQJBAHMDq-hHbOSBUCqVVuyskirQ3kzgOrFRlS5IF9U_xG5nxJqlCRW89cI3HyTiZZzyej5DnWjqFqNyU8RQSFFkk1ICfomPphJaFkEmRB7AJPZ2a2Sz5tEZ-d2dhsKyys4nBUOcLh__IN7lKwNtDtBy_Pf5BETUKd1c7CI2VWOz7k1-QstVv9t7D933B-c6Hw-1d2qIKUAfOtqGQkSnmY-AkAz60ijPphTIpxD1ZnIL7KowSWRpDapSBNdAyldwlRjDpjHc-FXDfS-Qy2HGNJWR61id4DPfwuoM5Rm3WDKF8KdbLQ_KnGDUD5xcwAs56grPVmX9t0QbPt3Pzf3tnt8iNNsaOtlZKcZus-fIOuTppqwjuko_bPfhitCiifI4w2idHUYHl5hB7R2mZR9hHoyp8hTTLBtbra7gGQ9Hkc4SwwlVzj3y5kGXcJ-vlovQPSOR8nOcO8vs8ETL23qSQV48dj0XOhfDJiLDuS1vXdltH0I8jG7Iuo-xKOixIhw3SYc2IvOrnHK96jZxL_Q4FqKfEPuHhwqL6ZluzY3NdCO-ZMnFWyMS5TI-1khgDemBTAZsvUfwsWjNgz6XtoQxYJPYFs1vY_AmbRsLjNgaUYIXccLgTQdtawdqeyt-IPOuHcSZW9pV-sUQak2BPID4eET0Q_MHKhiPl_HvohJ5wrQ2Dma87FTl9-L_f3MPzeX1Kru0eTg7swd50_xG5zoP-asrYBllvqqV_TK64n828rp4E7Y_I14tWnT89p4-a |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3daxQxEA9apfSlftOrVSMIPujSyyabj8daPRXtUahK38JuNrEHZa_s7RX8753JfuhaFcTXZEKSyUwyw0x-Q8gzJZzEqtwJS3NwUEQwiYZ3KpkKx5UIXJhQxmITaj7Xp6fm-Kdf_DHbvQ9Jtn8aEKWpavYvytCquJb7K4ZFchPMRAe3SrJEXyc3BBYNQn_95MsQR8CoWv9V5rfjRs9RRO2_ejdfzZf8JWga36LZrf_fxW2y3dmh9KAVnDvkmq_uks2jLtJ-j7w9HAoU0mWg5QJLTX87pwFTssE-pXlVUsSaqIOvkWbdwAL8Ctqgix6dUCy9Wzf3yefZm0-H75Ku6ELiwBZpEnBYJfMZHFQBx6RkVgjPpc7BLCyyHF73oCUv8gw8xwIuSyVykTqjORNOe-dz_oBsVMvK7xDqfFaWDnzg0nCRea9z8D2nLs14mXLuzYSwnvfWdYjkWBjj3EbPREvbcsgCh2zkkNUT8mIYc9HicfyV-hUe6UCJWNqxYVl_tZ1q2lIF7j2TOiuCMM4VaqqkQDvJwzIlLPM5CoRFjYflubz7uACbROwse4AASQisCNPtjShBU924uxcp290UK5tKA1YseIHZhDwdunEkZr9VfrlGGm0QNyedTogaieJoZ-OeanEW0cJNqpRmMPJlL5A_Jv8z53b_jfwJ2Tx-PbMf388_PCRbaRRplTC2Rzaaeu0fkZvuslms6sdRPb8D44Y26g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+dimethyl+fumarate+and+interferon+outcomes+in+an+MS+cohort&rft.jtitle=BMC+neurology&rft.au=Sattarnezhad%2C+Neda&rft.au=Healy%2C+Brian+C&rft.au=Baharnoori%2C+Moogeh&rft.au=Diaz-Cruz%2C+Camilo&rft.date=2022-07-11&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2377&rft.eissn=1471-2377&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12883-022-02761-8&rft.externalDocID=A710030878 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon |